Safety and Outcomes of Immune Checkpoint Inhibitor Therapy in Systemic Sclerosis: A Scoping Review
With their success in the treatment of various malignancies, immune checkpoint inhibitors (ICIs) are quickly being established as a critical component of treatment plans in oncology. However, due to concerns regarding autoimmune flares and immune-related adverse events, patients with autoimmune disease have historicall...